CN102216448A - Foxp3+天然杀伤t细胞及免疫相关疾病的治疗 - Google Patents

Foxp3+天然杀伤t细胞及免疫相关疾病的治疗 Download PDF

Info

Publication number
CN102216448A
CN102216448A CN2009801452249A CN200980145224A CN102216448A CN 102216448 A CN102216448 A CN 102216448A CN 2009801452249 A CN2009801452249 A CN 2009801452249A CN 200980145224 A CN200980145224 A CN 200980145224A CN 102216448 A CN102216448 A CN 102216448A
Authority
CN
China
Prior art keywords
cells
foxp3
cell
natural killer
nkt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801452249A
Other languages
English (en)
Chinese (zh)
Inventor
路易斯·里卡多·西蒙斯·达·席尔瓦·格拉萨
玛尔塔·索非亚·费雷拉·蒙泰罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Lisboa
Instituto de Medicina Molecular Joao Lobo Antunes
Original Assignee
Universidade de Lisboa
Instituto de Medicina Molecular Joao Lobo Antunes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Lisboa, Instituto de Medicina Molecular Joao Lobo Antunes filed Critical Universidade de Lisboa
Publication of CN102216448A publication Critical patent/CN102216448A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801452249A 2008-11-13 2009-11-13 Foxp3+天然杀伤t细胞及免疫相关疾病的治疗 Pending CN102216448A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11436208P 2008-11-13 2008-11-13
US61/114,362 2008-11-13
PT10476409 2009-09-25
PT104764 2009-09-25
PCT/PT2009/000060 WO2010056144A2 (en) 2008-11-13 2009-11-13 Foxp3+ natural kiler t-cells and the treatment of immune related diseases

Publications (1)

Publication Number Publication Date
CN102216448A true CN102216448A (zh) 2011-10-12

Family

ID=42138978

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801452249A Pending CN102216448A (zh) 2008-11-13 2009-11-13 Foxp3+天然杀伤t细胞及免疫相关疾病的治疗

Country Status (8)

Country Link
US (1) US20120114675A1 (enExample)
EP (1) EP2356222A2 (enExample)
JP (1) JP2012508575A (enExample)
CN (1) CN102216448A (enExample)
AU (1) AU2009314704A1 (enExample)
BR (1) BRPI0915255A2 (enExample)
CA (1) CA2743502A1 (enExample)
WO (1) WO2010056144A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603892A (zh) * 2012-02-22 2012-07-25 尉军 一种肿瘤标志物foxp3自身抗体及应用
CN105039255A (zh) * 2015-09-09 2015-11-11 广州赛莱拉干细胞科技股份有限公司 一种nkt细胞诱导培养的添加剂及诱导培养的方法
CN106047808A (zh) * 2015-04-07 2016-10-26 富禾生医股份有限公司 经修饰的自然杀伤t细胞、医药组合物和其用途
CN114081946A (zh) * 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123821C2 (uk) * 2014-06-11 2021-06-09 Полібіосепт Гмбх Композиція для експансії лімфоцитів in vitro
CN107475194B (zh) * 2017-10-09 2018-07-24 天津长和生物技术有限公司 Nkt细胞培养基、培养方法及二者的应用
WO2020215034A1 (en) * 2019-04-19 2020-10-22 The Regents Of The University Of California An ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
KR20230017786A (ko) 2020-04-28 2023-02-06 라이엘 이뮤노파마, 인크. 세포 배양 방법
WO2025221808A1 (en) * 2024-04-15 2025-10-23 Trustees Of Tufts College Efficient epigenetic reprogramming of t effector cells into stable regulatory t cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016192A1 (en) 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6759035B2 (en) * 2000-04-11 2004-07-06 University Of Southen California Method to prevent graft rejection using TGF-beta to induce T suppressor cells
DE60335817D1 (de) * 2002-10-25 2011-03-03 Us Government Verfahren zur prävention von tumorrezidiven durch blockade von tgf-beta

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603892A (zh) * 2012-02-22 2012-07-25 尉军 一种肿瘤标志物foxp3自身抗体及应用
CN114081946A (zh) * 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
CN106047808A (zh) * 2015-04-07 2016-10-26 富禾生医股份有限公司 经修饰的自然杀伤t细胞、医药组合物和其用途
CN106047808B (zh) * 2015-04-07 2020-08-04 富禾生医股份有限公司 经修饰的自然杀伤t细胞、医药组合物和其用途
US10864232B2 (en) 2015-04-07 2020-12-15 FullHope Biomedical Co., Ltd. Modified natural killer T cells, pharmaceutical compositions and uses thereof
CN105039255A (zh) * 2015-09-09 2015-11-11 广州赛莱拉干细胞科技股份有限公司 一种nkt细胞诱导培养的添加剂及诱导培养的方法

Also Published As

Publication number Publication date
WO2010056144A3 (en) 2010-07-22
JP2012508575A (ja) 2012-04-12
CA2743502A1 (en) 2010-05-20
BRPI0915255A2 (pt) 2018-02-06
WO2010056144A2 (en) 2010-05-20
EP2356222A2 (en) 2011-08-17
AU2009314704A1 (en) 2010-05-20
US20120114675A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
US12421293B2 (en) Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
Roncarolo et al. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications
Lerret et al. Donor-specific CD8+ Foxp3+ T cells protect skin allografts and facilitate induction of conventional CD4+ Foxp3+ regulatory T cells
JP2022034067A (ja) Ｔ細胞調節方法
CN102216448A (zh) Foxp3+天然杀伤t细胞及免疫相关疾病的治疗
US9018006B2 (en) Stable Tregs and related materials and methods
Pedros et al. Disrupted regulatory T cell homeostasis in inflammatory bowel diseases
Asnagli et al. Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis
CN111601882A (zh) 工程化的免疫细胞的应用和生产
Conti‐Fine et al. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis
US20230210902A1 (en) Sars-cov-2-specific t cells
US20210236512A1 (en) Clozapine for the treatment of a immunoglobulin driven b cell disease
JP2023021131A (ja) 免疫を調節するペプチド、ポリペプチド又は細胞を作製する方法
CA2316089A1 (en) Novel cells and molecules involved in immune regulation
Li et al. Regulatory TCRαβ+ double negative T cells suppress γδ T cells and alleviate colitis
Bennett Glucocorticoid Induced Leucine Zipper: Gatekeeper for CD8+ T cell activation and anti-viral responses
Haddad Divergent Effects of OX40L on Regulatory T Cell Phenotype and Function: Implications for Type 1 Diabetes Therapy
Meyer et al. NK Cells
Locafaro In vitro generation and in vivo characterization of IL-10 engineered T cells suitable for adoptive immunotherapy
Human Q-Independent, CD1d-Restricted α 24-J
Schenk et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels
Zhao Identifying the defects in mechanisms regulating effector: Regulatory cell equilibrium in a mouse model of type 1 diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111012